Red yeast rice: the hidden statin Europe wants to ban

Red yeast rice: the hidden statin Europe wants to ban
SupplementsImage de l’article

The short answer

Red yeast rice lowers cholesterol because it contains a statin. Its monacolin K is chemically identical to lovastatin, a prescription drug. Europe first capped its dose at less than 3 mg per day in 2022, then withdrew the health claim in 2024, and a 2026 proposal would ban it entirely.

The authorities’ reasoning is simple. At doses that meaningfully lower cholesterol, around 10 mg, red yeast rice carries the side effects of a statin. At legal doses, below 3 mg, its effectiveness has not been established, and the European Food Safety Authority (EFSA) has found no safe dose.

A statin without a prescription, without reliable dosing and without medical monitoring, marketed as a natural alternative to statins: one of the finest paradoxes in the supplement aisle.

A statin in a capsule

Red yeast rice is rice fermented by a mold, Monascus purpureus. During fermentation, it produces monacolins. The main one, monacolin K, is identical to lovastatin in its lactone form, as noted by EFSA and the 2022 EU regulation. It blocks the same enzyme as all statins, the one that allows the liver to make cholesterol.

The United States drew a legal conclusion from this back in 2007. The FDA issued a warning about three products containing lovastatin, the active ingredient in a medicine, and classified them as unapproved drugs. According to the NCCIH, a product with added or concentrated lovastatin cannot be sold as a supplement in the United States.

The second problem is dosing. Because the content depends on fermentation, it varies enormously from one package to the next:

  • 12 US products analyzed in 2010 contained 0.10 to 10.09 mg of monacolin K per capsule, a 100-fold difference
  • 28 brands analyzed in 2017 provided 0.09 to 10.94 mg per day at the recommended dose, and 2 contained none at all
  • 35 products bought online in the EU in 2024: roughly one in ten had problems, due to excess monacolins or bacterial contamination

A medicine whose dose varies 100-fold depending on the brand would never be approved. As a supplement, that was the norm.

It works, and that is precisely the problem

Unlike many supplements, red yeast rice has a measurable effect. A 2015 meta-analysis of 20 studies found an LDL reduction of about 1 mmol/L, or nearly 39 mg/dL, compared with placebo, with no clear difference compared with a statin. Another review in 2023 found a reduction of about 29 mg/dL.

In China, a large trial, the CCSPS, even followed nearly 5,000 patients after a heart attack for 4.5 years, using a standardized extract, Xuezhikang. Major coronary events fell from 10.4% with placebo to 5.7%. That is the result you would expect from a statin, which makes sense: it is one.

Cardiologists’ views have shifted. The 2019 European lipid guidelines noted cholesterol reductions of up to 20% with 2.5 to 10 mg of monacolin K per day, and considered these products for people who did not qualify for statin treatment. Their 2025 update is stricter: it finds that convincing evidence of clinical benefit is lacking for red yeast rice, and does not support supplements whose safety and LDL-lowering effectiveness are undocumented.

The side effects of a statin, without the monitoring

A prescribed statin comes with a doctor who chooses the dose, checks interactions and monitors your muscles and liver. Red yeast rice comes with none of that.

In France, ANSES published an opinion in 2014 after receiving 30 reports through its nutrivigilance system. Of the 25 cases that could be analyzed:

  • 9 cases of muscle damage and 8 cases of liver damage
  • 2 allergic reactions, and among the cases with the most probable links, one case of Stevens–Johnson syndrome, a severe reaction affecting the skin and mucous membranes
  • a highly likely link in 2 cases, likely in 10 and possible in 8

The agency concluded that these products pose a health risk to some consumers.

EFSA went further in 2018. It considered safety a major concern at 10 mg per day, the dose required for the health claim at the time. It also noted severe cases at doses as low as 3 mg per day, including rhabdomyolysis, muscle breakdown that can damage the kidneys, and liver damage. The 2022 regulation states that these cases occurred after two weeks to one year of use, and that some required hospitalization. Crucially, EFSA identified no safe daily dose.

There is a counterargument. A 2019 meta-analysis of 53 trials involving 8,535 participants found no more muscle problems than with placebo. But these trials were short and small, and were not designed to detect rare adverse effects. That is precisely what case reports pick up.

What Europe has decided

2022: a limit below 3 mg

The Regulation (EU) 2022/860, which entered into force on June 22, 2022 with no transition period, requires a daily serving to provide less than 3 mg of monacolins. The label must state the content per serving and carry specific warnings:

  • must not be consumed by pregnant or breastfeeding women, anyone under 18 or anyone over 70
  • must not be consumed if you take medication to lower your cholesterol
  • must not be consumed if you already take other products containing red yeast rice
  • if you have a health problem, ask your doctor for advice

2024: the health claim disappears

Until 2024, the EU permitted the claim “monacolin K from red yeast rice contributes to the maintenance of normal blood cholesterol levels,” provided the product supplied 10 mg per day. The 3 mg limit made that promise legally impossible to fulfill. Regulation (EU) 2024/2041 therefore removed it, effective August 19, 2024.

For two years, the law permitted a claim that required a prohibited dose. That shows just how awkwardly this product sits between supplement and medicine.

2026: toward a total ban

In 2025, EFSA reviewed the data submitted by manufacturers to defend doses below 3 mg. Its conclusion: the data do not establish their safety.

The Commission prepared a draft regulation moving monacolins onto the list of substances prohibited in foods. Products already on the market could remain there for 12 months after it enters into force. The text was submitted to the French Parliament on July 15, 2026, the same day as the proposal targeting senna and other laxative plants. As of November 21, 2026, I have not found its publication in the Official Journal: the ban is therefore not yet in force.

5 recalls in France

The dietary supplement recall tracker lists 5 recalls of red yeast rice products, involving 5 brands:

  • 4 for excessive monacolin content, between November 2022 and August 2024, after the limit came into force
  • 1 for ethylene oxide in 2021, which came from the capsule shell

The latest, in August 2024, is telling: the product provided 4.4 mg of monacolins per capsule, exceeding the 3 mg daily limit in a single dose.

Citrinin, the other fermentation risk

The mold that produces monacolins can also make citrinin, a mycotoxin that is toxic to the kidneys in animals and which ANSES describes as genotoxic. In 2010, 4 of the 12 US products analyzed contained high levels.

The EU sets a limit for supplements based on fermented rice. It was lowered from 2,000 to 100 µg per kilogram by Regulation (EU) 2019/1901, applicable since April 1, 2020. A “citrinin-free” label is still a manufacturer’s promise, not a test result you can verify.

The Kobayashi case: a manufacturing tragedy

In March 2024, Japan discovered severe kidney damage in consumers of Kobayashi red yeast rice supplements sold for cholesterol. Japan’s health ministry ordered the destruction of three products.

The investigation found the cause. According to the ministry’s working group, a mold present in the factory, Penicillium adametzioides, had contaminated the culture and produced puberulic acid, which is toxic to the kidneys in rats. Two other compounds were monacolin K transformed by this mold, with no kidney toxicity.

The damage involved lesions in the kidney tubules, known as Fanconi syndrome, rather than muscle breakdown. In a series of 192 patients, 87% still had reduced kidney function at the last measurement. The ministry counted deaths as product-related only when they involved both a contaminated batch and kidney damage: its experts identified 13 over the course of their meetings. As of June 30, 2025, 2,727 nonfatal cases had been investigated.

This case tells us nothing about monacolin itself. It shows something else: a supplement made through fermentation depends entirely on the quality of the factory, and no one monitors its contents as closely as those of a medicine.

Who should avoid it

ANSES and the mandatory warnings identify people who should not take it unless advised otherwise by a doctor:

  • people taking a statin or another cholesterol treatment, and those who stopped a statin because they could not tolerate it
  • pregnant or breastfeeding women, anyone under 18 and anyone over 70
  • people with renal impairment, muscle disease, untreated hypothyroidism or active liver disease
  • heavy consumers of alcohol or grapefruit juice, more than one liter per day according to ANSES

Some medicines greatly increase the amount of monacolin K in the blood, just as with a statin: fibrates, azole antifungals, certain macrolide antibiotics, antiarrhythmics and HIV treatments. Always tell your doctor and pharmacist if you take a red yeast rice supplement.

What really works for cholesterol

If your LDL is high, the right question is not “which supplement?” but “what is my cardiovascular risk?” That determines whether you need medication, and which one. The article on lowering LDL cholesterol without a statin · FR details what diet, fiber and physical activity can do, and the prescription alternatives when a statin is poorly tolerated.

A prescribed statin has an exact dose, a patient information leaflet, medical monitoring and decades of trials on heart attacks and mortality. Red yeast rice has the same molecule, without any of those advantages.

When to see a doctor

Some situations call for prompt medical advice:

  • stop taking the product and see a doctor if you experience unusual muscle pain, cramps or weakness, especially with dark urine
  • also see a doctor if you develop jaundice, unusual fatigue or pain under your ribs on the right side
  • discuss it before starting if you take long-term medication or have kidney, liver or muscle disease
  • have your cardiovascular risk assessed if your LDL is high, rather than self-medicating

The Verdict

Main sources


Frequently Asked Questions (FAQ)

  • Is red yeast rice a natural statin?

    Yes, chemically speaking. Its main active compound, monacolin K, is identical to lovastatin, a prescription statin. That is why it lowers LDL cholesterol, and why it can cause the same side effects as a statin, particularly muscle and liver problems, without the medical supervision that comes with a prescription.

  • Is red yeast rice banned in France?

    Not completely, as of November 21, 2026. Since June 2022, a daily serving must provide less than 3 mg of monacolins, with mandatory warnings. Since August 2024, the cholesterol claim has been removed. A draft EU regulation would ban monacolins in foods entirely, allowing 12 months to sell existing stocks, but I have not found its publication in the Official Journal.

  • Can you take red yeast rice with a statin?

    No. The mandatory label says so: do not consume it if you take cholesterol-lowering medication. That amounts to taking two statins together. ANSES also advises against it for people who stopped taking a statin because they could not tolerate it, unless advised otherwise by a doctor, since monacolin K is itself a statin.

  • What are the side effects of red yeast rice?

    The same as those of statins. ANSES analyzed 25 reports, mainly involving muscle and liver damage, and rarer cases such as a severe skin reaction. The European Food Safety Authority noted severe cases at doses as low as 3 mg of monacolins per day, including muscle breakdown. Stop taking the product and see a doctor if you experience muscle pain or weakness, dark urine or jaundice.

  • What happened with red yeast rice in Japan?

    In 2024, supplements made by Kobayashi caused severe kidney damage. Japan’s health ministry identified a mold at the factory that produced a kidney toxin, puberulic acid. This was manufacturing contamination, not an effect of monacolin. Ministry experts identified 13 deaths that met their criteria, and 2,727 nonfatal cases were investigated.

Partager cet article

X f in

Keep exploring

View all articles

Supplements

Fat burners: effective or dangerous? What trials show

Read the article

Supplements

Vitamin B3 (niacin): flushing, risks and the form not to confuse it with

Read the article

Supplements

Horsetail for hair and nails: what the capsules are worth

Read the article